OraSure gains sublicence to HIV-2 patent:
This article was originally published in Clinica
OraSure Technologies, the Bethlehem, Pennsylvania developer of oral fluid diagnostics, has obtained a worldwide, non-exclusive sublicence to certain HIV-2 patents held by Bio-Rad Laboratories. This agreement enables OraSure to sell its OraQuick rapid HIV-1 and -2 point-of-care (POC) tests on a global basis. Bio-Rad is the exclusive licensee of the HIV-2 patents under an agreement with the Institut Pasteur of Paris in France.